C
Christina I. Herold
Researcher at Harvard University
Publications - 23
Citations - 1523
Christina I. Herold is an academic researcher from Harvard University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 10, co-authored 17 publications receiving 1287 citations. Previous affiliations of Christina I. Herold include Duke University & Durham University.
Papers
More filters
Journal ArticleDOI
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.
Andrew J. Armstrong,Matthew S. Marengo,Sebastian Oltean,Sebastian Oltean,Gabor Kemeny,Rhonda L. Bitting,James D. Turnbull,Christina I. Herold,Christina I. Herold,Paul K. Marcom,Daniel J. George,Mariano A. Garcia-Blanco +11 more
TL;DR: The existence and high frequency of these C TCs coexpressing epithelial, mesenchymal, and stem cell markers in patients with progressive metastases has important implications for the application and interpretation of approved methods to detect CTCs.
Journal ArticleDOI
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel
Nadine Tung,Chiara Battelli,Brian Allen,Rajesh R. Kaldate,Satish Bhatnagar,Karla R. Bowles,Kirsten Timms,Judy Garber,Christina I. Herold,Leif W. Ellisen,Jill Krejdovsky,Kim DeLeonardis,Kristin Sedgwick,Kathleen A. Soltis,Benjamin B. Roa,Richard J. Wenstrup,Anne-Renee Hartman +16 more
TL;DR: The authors assessed the frequency of deleterious germline mutations among individuals with breast cancer who were referred for BRCA1 and BRCa2 gene testing using a panel of 25 genes associated with inherited cancer predisposition.
Journal ArticleDOI
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Joyce F. Liu,Christina I. Herold,Kathryn P. Gray,Richard T. Penson,Neil S. Horowitz,Panagiotis A. Konstantinopoulos,Cesar M. Castro,Sarah J. Hill,Jennifer Curtis,Weixiu Luo,Ursula A. Matulonis,Stephen A. Cannistra,Don S. Dizon,Don S. Dizon +13 more
TL;DR: The nivolumab with bevacizumab combination appeared to show activity in patients with relapsed ovarian cancer, with greater activity in the platinum-sensitive setting, and alternative combinational strategies may be necessary in theatinum-resistant setting.
Journal ArticleDOI
Translational breast cancer research consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
Rachel A. Freedman,Rebecca Gelman,Jeffrey S. Wefel,Michelle E. Melisko,Kenneth R. Hess,Roisin M. Connolly,Catherine Van Poznak,Polly A. Niravath,Shannon Puhalla,Nuhad K. Ibrahim,Kimberly L. Blackwell,Beverly Moy,Christina I. Herold,Minetta C. Liu,Alarice C. Lowe,Nathalie Y. R. Agar,N. Ryabin,Sarah Farooq,Elizabeth V. Lawler,Mothaffar F. Rimawi,Ian E. Krop,Antonio C. Wolff,Eric P. Winer,Nan Lin +23 more
TL;DR: Although neratinib had low activity and did not meet the threshold for success, 12.5% of patients received six or more cycles, and patients in the study experienced a decreased quality of life over time.
Journal ArticleDOI
Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing
Christina I. Herold,Vijaya Chadaram,Bercedis L. Peterson,P. Kelly Marcom,Judith O. Hopkins,Gretchen Kimmick,Justin Favaro,Erika Hamilton,Renee Welch,Sarah S. Bacus,Kimberly L. Blackwell +10 more
TL;DR: There were no clinically meaningful decreases before and after dasatinib exposure between exploratory tissue biomarkers of Src inhibition which may be attributable to challenges in defining biomarker endpoints for multitargeted tyrosine kinase inhibitors.